BioLine RX Ltd (BLRX) - Total Liabilities

Latest as of September 2025: ILA20.27 Million ILA ≈ $54.35K USD

Based on the latest financial reports, BioLine RX Ltd (BLRX) has total liabilities worth ILA20.27 Million ILA (≈ $54.35K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore BioLine RX Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.

BioLine RX Ltd - Total Liabilities Trend (2005–2024)

This chart illustrates how BioLine RX Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see BLRX current and non-current assets.

BioLine RX Ltd Competitors by Total Liabilities

The table below lists competitors of BioLine RX Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Radiant Utama Interinsco Tbk JK:RUIS	Indonesia	Rp711.69 Billion
Jwwinvest WAR:JWW	Poland	zł43.88 Million
Danish Aerospace Company A/S CO:DAC	Denmark	Dkr23.02 Million
Savannah Goldfields Ltd AU:SVG	Australia	AU$33.16 Million
PHOENIX NEW MED.ADR 1/48 F:1PX	Germany	€541.47 Million
Lions Bay Capital Inc V:LBI	Canada	CA$3.22 Million
Trainline Plc LSE:TRN	UK	GBX452.09 Million

Liability Composition Analysis (2005–2024)

This chart breaks down BioLine RX Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See BioLine RX Ltd (BLRX) balance sheet quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.09	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.04	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.51	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how BioLine RX Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for BioLine RX Ltd (2005–2024)

The table below shows the annual total liabilities of BioLine RX Ltd from 2005 to 2024.

Year	Total Liabilities	Change
2024-12-31	ILA25.45 Million ≈ $68.22K	-49.81%
2023-12-31	ILA50.70 Million ≈ $135.93K	+98.50%
2022-12-31	ILA25.54 Million ≈ $68.48K	+91.99%
2021-12-31	ILA13.30 Million ≈ $35.67K	-47.33%
2020-12-31	ILA25.26 Million ≈ $67.72K	+25.13%
2019-12-31	ILA20.19 Million ≈ $54.12K	+35.37%
2018-12-31	ILA14.91 Million ≈ $39.98K	+84.46%
2017-12-31	ILA8.08 Million ≈ $21.67K	+106.65%
2016-12-31	ILA3.91 Million ≈ $10.49K	+5.96%
2015-12-31	ILA3.69 Million ≈ $9.90K	-16.09%
2014-12-31	ILA4.40 Million ≈ $11.80K	-46.76%
2013-12-31	ILA8.27 Million ≈ $22.16K	-11.47%
2012-12-31	ILA9.34 Million ≈ $25.03K	+37.18%
2011-12-31	ILA6.81 Million ≈ $18.25K	-69.96%
2010-12-31	ILA22.65 Million ≈ $60.73K	-45.06%
2009-12-31	ILA41.23 Million ≈ $110.54K	+10.41%
2008-12-31	ILA37.34 Million ≈ $100.11K	+51.61%
2007-12-31	ILA24.63 Million ≈ $66.03K	+15.27%
2006-12-31	ILA21.37 Million ≈ $57.29K	+173.07%
2005-12-31	ILA7.83 Million ≈ $20.98K	--

About BioLine RX Ltd

TA:BLRX Israel Biotechnology

Market Cap

$9.10 Million

ILA3.39 Billion ILA

Market Cap Rank

#27406 Global

#389 in Israel

Share Price

ILA1.30

Change (1 day)

+0.00%

52-Week Range

ILA1.20 - ILA2.30

All Time High

ILA618.30